These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36374708)

  • 1. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Turbyfill C; Adams K; Tenforde MW; Murray NL; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Clark Files D; Hager DN; Shehu A; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Lauring AS; Khan A; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; June Gordon A; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Rhoads JP; Lindsell CJ; Hart KW; McMorrow M; Surie D; Self WH; Patel MM
    Vaccine; 2022 Nov; 40(48):6979-6986. PubMed ID: 36374708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors.
    Doll MK; Pettigrew SM; Ma J; Verma A
    Clin Infect Dis; 2022 Aug; 75(1):e564-e571. PubMed ID: 35325923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Payne AB; Ciesla AA; Rowley EAK; Weber ZA; Reese SE; Ong TC; Vazquez-Benitez G; Naleway AL; Klein NP; Embi PJ; Grannis SJ; Kharbanda AB; Gaglani M; Tenforde MW; Link-Gelles R;
    Vaccine; 2023 Dec; 41(51):7581-7586. PubMed ID: 38000964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
    Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
    JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network.
    Tenforde MW; Weber ZA; DeSilva MB; Stenehjem E; Yang DH; Fireman B; Gaglani M; Kojima N; Irving SA; Rao S; Grannis SJ; Naleway AL; Kirshner L; Kharbanda AB; Dascomb K; Lewis N; Dalton AF; Ball SW; Natarajan K; Ong TC; Hartmann E; Embi PJ; McEvoy CE; Grisel N; Zerbo O; Dunne MM; Arndorfer J; Goddard K; Dickerson M; Patel P; Timbol J; Griggs EP; Hansen J; Thompson MG; Flannery B; Klein NP
    J Infect Dis; 2023 Jul; 228(2):185-195. PubMed ID: 36683410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV.
    Chambers C; Samji H; Cooper CL; Costiniuk CT; Janjua NZ; Kroch AE; Arbess G; Benoit AC; Buchan SA; Chung H; Kendall CE; Kwong JC; Langlois MA; Lee SM; Mbuagbaw L; McCullagh J; Moineddin R; Nambiar D; Walmsley S; Anis AH; Burchell AN;
    AIDS; 2022 Dec; 36(15):F17-F26. PubMed ID: 36254892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.
    Tenforde MW; Patel MM; Lewis NM; Adams K; Gaglani M; Steingrub JS; Shapiro NI; Duggal A; Prekker ME; Peltan ID; Hager DN; Gong MN; Exline MC; Ginde AA; Mohr NM; Mallow C; Martin ET; Talbot HK; Gibbs KW; Kwon JH; Chappell JD; Halasa N; Lauring AS; Lindsell CJ; Swan SA; Hart KW; Womack KN; Baughman A; Grijalva CG; Self WH;
    Clin Infect Dis; 2023 Mar; 76(6):1030-1037. PubMed ID: 36327388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
    JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.
    Mazagatos C; Delgado-Sanz C; Monge S; Pozo F; Oliva J; Sandonis V; Gandarillas A; Quiñones-Rubio C; Ruiz-Sopeña C; Gallardo-García V; Basile L; Barranco-Boada MI; Hidalgo-Pardo O; Vazquez-Cancela O; García-Vázquez M; Fernández-Sierra A; Milagro-Beamonte A; Ordobás M; Martínez-Ochoa E; Fernández-Arribas S; Lorusso N; Martínez A; García-Fulgueiras A; Sastre-Palou B; Losada-Castillo I; Martínez-Cuenca S; Rodríguez-Del Águila M; Latorre M; Larrauri A;
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1014-1025. PubMed ID: 35880469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
    Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
    JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
    Surie D; Bonnell LN; DeCuir J; Gaglani M; McNeal T; Ghamande S; Steingrub JS; Shapiro NI; Busse LW; Prekker ME; Peltan ID; Brown SM; Hager DN; Ali H; Gong MN; Mohamed A; Khan A; Wilson JG; Qadir N; Chang SY; Ginde AA; Huynh D; Mohr NM; Mallow C; Martin ET; Lauring AS; Johnson NJ; Casey JD; Gibbs KW; Kwon JH; Baughman A; Chappell JD; Hart KW; Grijalva CG; Rhoads JP; Swan SA; Keipp Talbot H; Womack KN; Zhu Y; Tenforde MW; Adams K; Self WH; McMorrow ML
    Vaccine; 2023 Jun; 41(29):4249-4256. PubMed ID: 37301704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States.
    Tenforde MW; Patel MM; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Gaglani M; McNeal T; Ghamande S; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Gershengorn HB; Babcock HM; Kwon JH; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Olson SM; Stephenson M; Schrag SJ; Kobayashi M; Verani JR; Self WH;
    Clin Infect Dis; 2022 May; 74(9):1515-1524. PubMed ID: 34358310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.
    Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R
    BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
    Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Plumb ID; Fette LM; Tjaden AH; Feldstein L; Saydah S; Ahmed A; Link-Gelles R; Wierzba TF; Berry AA; Friedman-Klabanoff D; Larsen MP; Runyon MS; Ward LM; Santos RP; Ward J; Weintraub WS; Edelstein S; Uschner D
    Vaccine; 2023 Apr; 41(15):2596-2604. PubMed ID: 36932031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
    Urquidi C; Sepúlveda-Peñaloza A; Valenzuela MT; Ponce A; Menares V; Cortes CP; Benítez R; Santelices E; Anfossi R; Moller A; Santolaya ME
    Vaccine; 2024 Jul; 42(18):3851-3856. PubMed ID: 38749822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.